Experimental Drug Showed Promise as Weight Loss Adjunct
Adults with obesity who combined a new medication with semaglutide showed changes in markers of systemic inflammation.
Updated on Oct. 7, 2026 in Weight Loss
Live Poll
Would you choose an experimental drug combination if it promised better control of chronic inflammation?
Rezera Inc. announced results from its Phase 2 RESOLVE-2 trial, which evaluated the investigational drug ruvonoflast as an add-on therapy for adults with obesity already taking semaglutide. The study explored whether the combination could provide additional health benefits beyond existing weight loss treatments.
Why it matters
Researchers are investigating whether adjunctive therapies can address residual health risks in people using GLP-1 receptor agonists. By targeting inflammatory markers, this experimental approach aims to improve cardiovascular and metabolic outcomes for patients beyond weight management alone.
This Phase 2 trial of 82 adults randomized participants to receive either ruvonoflast or a placebo for 32 weeks alongside semaglutide. The study demonstrated additive reductions in hsCRP levels compared to semaglutide monotherapy, though these findings are preliminary.
The players
Rezera Inc.
A Boston-based biotechnology company focused on developing therapies for obesity and inflammatory conditions.
The details
The RESOLVE-2 trial tested ruvonoflast, an oral drug, to determine if it could augment the effects of semaglutide, a once-weekly subcutaneous medication. The study focused on measuring hsCRP, an inflammatory protein in the blood that acts as a marker for systemic inflammation and cardiovascular risk. By potentially lowering these markers further than semaglutide alone, researchers aim to address the residual inflammatory burden often seen in patients with obesity.
Timeline
October 7, 2026: Rezera announced the topline results for the RESOLVE-2 clinical trial.
November 6-9, 2026: The AHA Scientific Sessions are scheduled to take place in Chicago.
Health Landscape
This trial reflects a shift toward adjunctive therapies in the management of obesity and its associated cardiovascular risks. The presentation at the AHA Scientific Sessions follows a pattern of academic disclosure common in metabolic research.
This drug remains in the experimental phase and is not currently available for clinical use. If you are managing obesity with semaglutide, discuss any questions about your ongoing inflammatory markers or cardiovascular health goals with your physician.
The takeaway
Ruvonoflast is being studied as an add-on to semaglutide to potentially reduce systemic inflammation markers. Patients should maintain current treatment plans and discuss new research developments with their doctor before considering any changes to their care.
Further reading
For context on how emerging research influences current standards, visit the Weight Loss section.
Live Poll
Would you choose an experimental drug combination if it promised better control of chronic inflammation?
